Biotech · Public company · Palo Alto, CA, US

Evommune, Inc.

Ticker EVMN · SEC CIK 0002044725

Track this companyFree. Adds Evommune, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials62 recruiting or active

Pipeline programs7From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline7

EVO101Phase 2 · Atopic Dermatitis EczemaClinicalTrials.gov · fetched Nov 12, 2026
EVO756Phase 2 · Atopic DermatitisClinicalTrials.gov · fetched Nov 12, 2026
EVO756Phase 2 · Chronic Spontaneous UrticariaClinicalTrials.gov · fetched Nov 12, 2026
EVO756, Dose 1Phase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
EVO756, Dose 2Phase 2 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
Oral EVO756 300 mg QDPhase 2 · Chronic Inducible UrticariaClinicalTrials.gov · fetched Nov 12, 2026
Oral EVO756 50 mg BIDPhase 2 · Chronic Inducible UrticariaClinicalTrials.gov · fetched Nov 12, 2026

Study of EVO756 in Adults With MigrainePHASE2 · RECRUITING · started Jul 29, 2026ClinicalTrials.gov NCT07616128 · fetched Nov 12, 2026
Phase 2b Study of EVO756 in Adults With Atopic DermatitisPHASE2 · COMPLETED · started Aug 26, 2025ClinicalTrials.gov NCT07150845 · fetched Nov 12, 2026
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)PHASE2 · COMPLETED · started Mar 20, 2025ClinicalTrials.gov NCT06873516 · fetched Nov 12, 2026
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%EARLY_PHASE1 · RECRUITING · started Dec 3, 2024ClinicalTrials.gov NCT06645821 · fetched Nov 12, 2026
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible UrticariaPHASE2 · COMPLETED · started Aug 14, 2024ClinicalTrials.gov NCT06603220 · fetched Nov 12, 2026
Safety and Efficacy Study of EVO101 Topical Cream in Atopic DermatitisPHASE2 · COMPLETED · started Sep 27, 2022ClinicalTrials.gov NCT05579899 · fetched Nov 12, 2026